Russell T. Burke

TL;DR: Analyses of samples from patients with acute myeloid leukaemia reveal that drug response is associated with mutational status and gene expression; the generated dataset provides a basis for future clinical and functional studies of this disease.

TL;DR: The pre-clinical activity of idelalisib combined with the novel and selective Syk inhibitor GS-9973 in primary peripheral blood and bone marrow Chronic Lymphocytic Leukemia samples was evaluated and both PI3Kd and Syk inhibition reduced CLL survival and in combination induced synergistic growth inhibition and further disrupted chemokine signaling at nanomolar concentrations.

TL;DR: P 505-15 successfully inhibited SYK-mediated B-cell receptor signaling and decreased cell viability in NHL and CLL and combination treatment of primary CLL cells with P505-15 plus fludarabine produced synergistic enhancement of activity at nanomolar concentrations.

TL;DR: CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway.

TL;DR: A large functional genomic resource is expanded, avenues for mechanistic exploration and drug development, and tools for predicting outcome in AML are revealed, including a single gene, PEAR1, which is found to be among the strongest predictors of patient survival.